HALF MOON BAY, Calif., May 13 Personalized medicine ischanging the face of healthcare. Currently, pharmacogenomic tests can helpphysicians determine the right dosing schedule for warfarin or to predict thepotential for adverse drug reactions. In the near future, healthprofessionals will leverage protein-based biomarkers to predict drug safetyand efficacy and to detect disease earlier.
Singulex Inc., a company focused on advancing technologies for earlydisease detection, today announced that its CEO, Philippe Goix, Ph.D., ischairing a panel on personalized medicine at the Think Tomorrow Today Summit,sponsored by ThinkPanmure. Participants on the panel, entitled "Just for Me:Personalized Medicine," include Michael McKenna, Ph.D., CSO of TethysBiosciences and Kathryn Phillips, Ph.D., professor of health economics &health services research at UCSF.
"While pharmacogenomics represent much of the current activity inpersonalized medicine, they are only the tip of the iceberg," said PhilippeGoix, CEO of Singulex. "The utility of protein biomarkers could soon eclipsethat of pharmacogenomics, allowing much earlier disease detection and alsoenabling pharmaceutical companies to identify what patient populations willrespond to their drug and then to monitor those patients to measure diseaseregression."
Singulex has pioneered technology that increases the clinical utility ofbiomarkers using immunoassay technologies. Through collaborations withpharmaceutical and biotechnology companies and academic researchers, thecompany has shown specifically that the biomarker c Troponin I (cTnI), avalidated biomarker for cardiac necrosis, can be detected in healthy people.Singulex can also measure small changes in cTnI levels that indicate stress tothe heart, such as during treadmill stress tests, which other technologiescannot do.
Singulex develops and commercializes innovative technology solutions thatenable disease understanding and management for life science researchers andclinicians. Utilizing proprietary quantitative single molecule detectiontechnology, Singulex develops customized biomarker diagnostic systems that candetect and quantify normal and abnormal protein biomarkers in a variety ofbiological samples with extreme sensitivity and accuracy. Singulex iscurrently conducting several pilot studies with academic and moleculardiagnostic partners to validate the company's commercial digital moleculedetection platform, the Erenna(TM) Immunoassay System. Singulex's research anddevelopment facilities are located at the Center for Emerging Technologies inSt Louis, Missouri, and the company's commercial operations are based inAlameda, California. To learn more about Singulex, please visit us athttp://www.singulex.com.
SOURCE Singulex Inc.